Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase II | Prevention | Active | Not Specified | Other | Institut Jules Bordet NCT01658956 |
Summary
The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile neutropenia among patients with breast cancer, treated with chemotherapy and presenting with a low to moderate risk of developing febrile neutropenia.
Eligibility Criteria
Inclusion Criteria:
Breast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC, docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant
Exclusion Criteria:
Eligibility to receive reimbursed GCSF
Trial Lead Organizations/Sponsors
Institut Jules Bordet
Trial Sites
 |
|
|
|
| Belgium | |||
|
|||
| Brussels | |||
|
|||
| Institut Jules Bordet | |||
| Aspasia Georgala, MD | Ph: 3225413255 | ||
| Email: aspasia.georgala@bordet.be | |||
| Marianne Paesmans | Ph: 3225413399 | ||
| Email: marianne.paesmans@bordet.be | |||
| Aspasia Georgala, MD | Principal Investigator | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01658956
Information obtained from ClinicalTrials.gov on August 06, 2012
Back to Top
